Evonik Shares Navigate a Wall Street Rift Ahead of Earnings

Analysts diverge on Evonik ahead of Q1 results, with Jefferies upgrading to Hold and Goldman Sachs bullish. Stock up 27% YTD amid efficiency drive and methionine price recovery.

A stark divergence of opinion has emerged among analysts covering German specialty chemicals group Evonik, setting the stage for a pivotal first-quarter earnings report. While one major bank has abandoned a long-standing sell rating, another sees substantial upside, creating an unusual split in market sentiment just days before the company provides a crucial financial update.

The catalyst for the renewed debate was a rating change from Jefferies. On April 13, the investment bank upgraded Evonik shares from "Underperform" to "Hold," simultaneously raising its price target from €12.20 to €15.10. Analyst Helena Xu cited improved pricing discipline in the methionine business, easing margin pressures, and a 3% increase to the firm's 2026 EBITDA forecast as reasons for the shift. However, the new target still sits well below the recent share price of €16.91, indicating Jefferies believes the stock remains vulnerable to a pullback.

This cautious optimism is not universally shared. Goldman Sachs maintains a decidedly bullish stance, having recently increased its price target from €18 to €20 and reiterating a "Buy" recommendation. Analyst Georgina Fraser anticipates first-quarter adjusted EBITDA will surpass market estimates, supported by tight supply in C4 chemicals, favorable currency effects, and price increases in the Advanced Technologies division. Deutsche Bank occupies a middle ground, aligning its price target with Jefferies at €15 but keeping its "Hold" rating intact. The Frankfurt-based bank forecasts a significant 18% year-on-year decline in Q1 EBITDA to €461 million.

The conflicting analyst views unfold against a backdrop of strong recent share performance. Evonik's stock has climbed 16.5% since mid-March and is up nearly 27% year-to-date, trading notably above its 200-day moving average of €14.82. This technical strength has caught the attention of momentum investors, even as the company trades at a 28% discount to its sector peers—a gap wider than its three-year average discount of 17%.

Beyond the financial debate, Evonik is advancing operational initiatives aimed at long-term efficiency. On April 14, the company, in partnership with energy firm Uniper, commissioned a high-temperature heat pump at its Herne site. The pilot project captures low-grade industrial waste heat from chemical production and upgrades it for use in the local district heating network, potentially supplying around 1,000 households and cutting CO2 emissions by up to 1,750 tonnes annually. Designed as a blueprint for other industrial locations, the project is part of Evonik's broader "Evonik Tailor Made" efficiency program, which targets meaningful cost reductions by year-end.

All eyes now turn to May 8, when Evonik releases its first-quarter results. The report will test whether the recent price recovery in methionine and early efficiency gains are translating to the bottom line, or if the rally has gotten ahead of fundamentals. Management's full-year guidance remains an adjusted EBITDA range of €1.7 to €2.0 billion, with the market consensus hovering around €1.8 billion. Further clarity on capital returns will follow on June 3 at the Annual General Meeting, where the dividend will be decided. Jefferies analysts project that, following a recent dividend cut, coverage could rebound to over 200% by 2027, a significant increase from the historical average of approximately 120%.